| Name | ReNeuron Group |
|---|---|
| Epic | RENE |
| Isin | GB00BF5G6K95 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3.38p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £1.93 | Debt ratio | n/a |
| Shares in issue | 57.17 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -134.45 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -9.5 | 52-week high / low | 0.00p / 0.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | ReNeuron Group |
|---|---|
| Address | Pencoed Business Park, Pencoed, Bridgend, United Kingdom, CF35 5HY |
| Telephone | +44 (0) 203 819 8400 |
| Website | http://www.reneuron.com/ |
| Director | Position |
|---|---|
| Mr Iain G Ross | Executive Chairman |
| Ms Barbara Staehelin | Senior Independent Non-Executive Director |
| Mr Martin Walton | Independent Non-Executive Director |
| Dr Mike Owen | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/03/23 | 31/03/22 | 31/03/21 |
| Intangible asssets and goodwill | 0.19 | 0.19 | 0.19 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.81 | 0.85 | 0.87 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.68 | 1.93 | 0.44 |
| Cash and equivalents | 7.15 | 9.55 | 14.7 |
| Other current assets and asset held for resale | n/a | n/a | 1.83 |
| Total of all assets | 9.64 | 17.32 | 25.35 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 4.32 | 7.02 | 5.88 |
| Long term liabilities | 0.27 | 0.42 | 0.56 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 4.59 | 7.43 | 6.45 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 5.06 | 9.89 | 18.91 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.57 | 0.57 | 0.57 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -151.96 | -147.12 | -138.09 |
| Share premium account | 113.92 | 113.92 | 113.9 |
| Total equity | 5.06 | 9.89 | 18.91 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -7.12 | -11.23 | -12.91 |
| Pre-tax profit | -6.66 | -11.06 | -13.41 |